

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

VOLUNTARY LOCK-UP UNDERTAKINGS BY CERTAIN SHAREHOLDERS

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (“**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. Capitalized terms used in this announcement shall have the same meaning as defined in the 2021 annual report of the Company unless the context requires otherwise.

The board of directors (the “**Director**”) of the Company (the “**Board**”) has noted the recent unusual fluctuation in the price and trading volume movements of the shares of the Company (the “**Shares**”). The Company wishes to clarify that all current business development and operation of the Company remain normal. As of the date of this announcement, the Company is not aware of any change in the regulatory regime, which may result in a material negative impact on the business operations of the Group and clinical trial approvals in China and abroad in the future. The Company wishes to remind the Company’s shareholders and potential investors to rationally treat any information not officially published by the Company, and the Company’s shareholders and potential investors are advised to exercise caution when dealing in the Shares.

VOLUNTARY LOCK-UP UNDERTAKINGS BY CERTAIN SHAREHOLDERS

The Board hereby announces that the Company was notified by Dr. Yinxiang WANG (“**Dr. Wang**”), the chairman of the Board and chief executive officer of the Company that, for the purpose of expressing their confidence in the long term value of the Company, Dr. Wang and his spouse, Ms. Zhu SHEN (“**Ms. Shen**”), have undertaken on a voluntary basis to be subject to lock-up undertakings (the “**Lock-up Undertakings**”) made in favor of the Company only, with respect to their direct and indirect interest in the Shares. Dr. Wang further confirms that as of the date of this announcement, Dr. Wang and Ms. Shen have not disposed of any shares of the Company.

The details of the Lock-up Undertakings are set out as follows:

	Number of Shares held subject to the Lock-up Undertakings as at the date of this announcement	Approximate percentage of shareholding in the Company subject to the Lock-up Undertakings as at the date of this announcement	Last day subject to the Lock-up Undertakings
Yakovpharma Ltd ⁽¹⁾	62,855,000	8.15%	June 30, 2023
Johwpharma Ltd ⁽²⁾	36,875,000	4.78%	June 30, 2023
Wordspharma Ltd ⁽³⁾	5,653,975	0.73%	June 30, 2023
Total	105,383,975	13.66%	

Notes:

- (1) Yakovpharma Ltd, a limited liability company incorporated under the laws of the British Virgin Islands (“BVI”) which is wholly owned by Dr. Wang;
- (2) Johwpharma Ltd, a limited liability company incorporated under the laws of the BVI which is indirectly wholly owned by Dr. Wang and Ms. Shen, the spouse of Dr. Wang;
- (3) Wordspharma Ltd is a limited liability company incorporated in the BVI and is wholly-owned by Ms. Shen, Dr. Wang’s spouse.

On behalf of the Board of Directors
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, June 30, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Ge WU and Dr. Daqing CAI as independent non-executive Directors.